#Icad results canada software

Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. It uses a proprietary miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body.ДЇor more information, visit and Forward-Looking StatementsД¬ertain statements contained in this News Release constitute вЂњforward-looking statementsвЂќ within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the future prospects for the CompanyвЂ™s technology platforms and products. The XoftВ® AxxentВ® Electronic Brachytherapy (eBxВ®) SystemВ® is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. Additionally, ProFound AI for DBT improved radiologist sensitivity by 8 percent and reduced unnecessary patient recall rates by 7.2 percent.

It offers clinically proven time-savings benefits to radiologists, including a reduction of reading time by 52.7 percent, thereby halving the amount of time it takes radiologists to read 3D mammography datasets.

#Icad results canada software

In 2018, ProFound AI for Digital Breast Tomosynthesis (DBT) became the first artificial intelligence (AI) software for DBT to be FDA-cleared it was also CE marked and Health Canada licensed that same year. ProFound AIв„ў is a high-performing workflow solution for 2D and 3D mammography, or digital breast tomosynthesis (DBT), featuring the latest in deep-learning artificial intelligence. Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. I look forward to working with the Company as we continue to drive this leading-edge treatment option forward.вЂќ

вЂњThe Xoft System is an innovative radiation oncology treatment solution that offers significant cost, mobility, and treatment time advantages to clinicians and patients alike. вЂњI look forward to returning to the Xoft team, especially during this particularly exciting time as iCAD explores new applications for Xoft for the treatment of various types of tumors,вЂќ said Mr. He earned a BA in Finance from the University of St. His areas of expertise include commercial strategy, business development, and product management. He has held a range of executive management and senior-level sales positions at Triple Ring Technologies, Terason Inc., Xoft Inc., GE Healthcare and Color Kinetics. Sirek has had a distinguished corporate career as a visionary leader and an expert in sales, marketing management and commercial operations, including product management, manufacturing, distribution, and engineering. SirekвЂ™s strong history of consistent results and experience within the medical industry will be a valuable contribution to the Company.вЂќ вЂњAs we begin to expand the Xoft System into emerging applications, such as in the brain, prostate, and rectal cancer space, with promising early clinical data within these areas stemming from research across a number of prestigious sites worldwide, we are confident Mr. He brings to the team a proven track record of high sales productivity, brand development, marketing success, and revenue growth,вЂќ said Stacey Stevens, President of iCAD. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Jeffrey Sirek was appointed as Senior Vice President and General Manager of Xoft. NASHUA, N.H., J(GLOBE NEWSWIRE) - iCAD, Inc.